Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-EARLY
2022-501073-40-00Phase 4Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 11
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in hemoglobin A1c. Planned start Jan 2023; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-501073-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501073-40-00.